Navidea Biopharmaceuticals IncFRA Navidea Stock Report

Navidea Biopharmaceuticals, Inc. engages in the development and commercialization of precision immunodiagnostic agents and immunotherapeutic. The company is headquartered in Dublin Ohio, Ohio and currently employs 11 full-time employees. The firm is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The firm is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of undetected disease. Its business is focused on two primary types of drug products, such as diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform, and therapeutic development programs, including therapeutic applications of its Manocept platform. The firm has developed processes for producing the first two therapeutic Manocept immuno-construct series, the Manocept doxorubicin (MAN-DOX) series, which targets activated CD206+ macrophages, and the Manocept dexamethasone (MAN-DEX) series, which inhibits the inflammatory activity of activated CD206+ macrophages.